PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice by Filipsson, K et al.
  
 University of Groningen
PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice
Filipsson, K; Pacini, G; Scheurink, AJW; Ahren, B
Published in:
American Journal of Physiology - Endocrinology and Metabolism
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
1998
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Filipsson, K., Pacini, G., Scheurink, AJW., & Ahren, B. (1998). PACAP stimulates insulin secretion but
inhibits insulin sensitivity in mice. American Journal of Physiology - Endocrinology and Metabolism, 274(5),
834 - 842.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
 274:834-842, 1998. Am J Physiol Endocrinol Metab
Karin Filipsson, Giovanni Pacini, Anton J. W. Scheurink and Bo Ahrén 
 You might find this additional information useful...
30 articles, 15 of which you can access free at: This article cites 
 http://ajpendo.physiology.org/cgi/content/full/274/5/E834#BIBL
10 other HighWire hosted articles, the first 5 are: This article has been cited by 
  
 [PDF]  [Full Text]  [Abstract]
, October 1, 2001; 281 (4): E693-E703. Am J Physiol Endocrinol Metab
G. Pacini, K. Thomaseth and B. Ahren 
 in mice
Contribution to glucose tolerance of insulin-independent vs. insulin-dependent mechanisms
  
 [PDF]  [Full Text]  [Abstract]
, February 1, 2002; 51 (90001): S212-220. Diabetes
R. N. Bergman, M. Ader, K. Huecking and G. Van Citters 
 Accurate Assessment of {beta}-Cell Function: The Hyperbolic Correction
  
 [PDF]  [Full Text]  [Abstract]
, May 1, 2002; 51 (5): 1453-1460. Diabetes
Yung, S. Hamren, J. N. Livingston and C. Q. Pan 
M. Tsutsumi, T. H. Claus, Y. Liang, Y. Li, L. Yang, J. Zhu, F. Dela Cruz, X. Peng, H. Chen, S. L.
 and Glucose Disposal: A Potential Therapy for Type 2 Diabetes
A Potent and Highly Selective VPAC2 Agonist Enhances Glucose-Induced Insulin Release
  
 [PDF]  [Full Text]  [Abstract]
, July 1, 2006; 291 (1): R131-R137. Am J Physiol Regulatory Integrative Comp Physiol
B. Ahren and G. Pacini 
 with a dominant-negative mutant hepatocyte nuclear factor-1{alpha}
A novel approach to assess insulin sensitivity reveals no increased insulin sensitivity in mice
  
 [PDF]  [Full Text]  [Abstract]
, May 1, 2009; 296 (5): R1316-R1324. Am J Physiol Regulatory Integrative Comp Physiol
G. Pacini, M. Ahren and B. Ahren 
 sensitivity in mice
Reappraisal of the intravenous glucose tolerance index for a simple assessment of insulin
on the following topics: 
 http://highwire.stanford.edu/lists/artbytopic.dtlcan be found at Medline items on this article's topics 
Physiology .. Mice 
Neuroscience .. Epinephrine 
Oncology .. Insulin Sensitivity 
Oncology .. Insulin Secretion 
Medicine .. Insulin 
Oncology .. Adrenaline 
including high-resolution figures, can be found at: Updated information and services 
 http://ajpendo.physiology.org/cgi/content/full/274/5/E834
 can be found at: AJP - Endocrinology and Metabolismabout Additional material and information 
 http://www.the-aps.org/publications/ajpendo
This information is current as of September 16, 2009 . 
  
 http://www.the-aps.org/.
20814-3991. Copyright © 2005 by the American Physiological Society. ISSN: 0193-1849, ESSN: 1522-1555. Visit our website at 
organization. It is published 12 times a year (monthly) by the American Physiological Society, 9650 Rockville Pike, Bethesda MD 










PACAP stimulates insulin secretion but inhibits
insulin sensitivity in mice
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Filipsson, Karin, Giovanni Pacini, Anton J. W. Scheu-
rink, and Bo Ahre´n. PACAP stimulates insulin secretion
but inhibits insulin sensitivity in mice. Am. J. Physiol. 274
(Endocrinol. Metab. 37): E834–E842, 1998.—Although pitu-
itary adenylate cyclase-activating polypeptide (PACAP) stimu-
lates insulin secretion, its net influence on glucose homeosta-
sis in vivo has not been established. We therefore examined
the action of PACAP-27 and PACAP-38 on insulin secretion,
insulin sensitivity, and glucose disposal as derived from the
minimal model of glucose disappearance during an intrave-
nous glucose tolerance test in anesthetized mice. PACAP-27
and PACAP-38 markedly and equipotently potentiated glu-
cose-stimulated insulin secretion, with a half-maximal effect
at 33 pmol/kg. After PACAP-27 or PACAP-38 (1.3 nmol/kg),
the acute (1–5 min) insulin response was 3.8 6 0.4 nmol/l
(PACAP-27) and 3.3 6 0.3 nmol/l (PACAP-38), respectively,
vs. 1.4 6 0.1 nmol/l after glucose alone (P , 0.001), and the
total area under the curve for insulin (AUCinsulin) was potenti-
ated by 60% (P , 0.001). In contrast, PACAP-27 and
PACAP-38 reduced the insulin sensitivity index (SI) [0.23 6
0.04 1024 min21/(pmol/l) for PACAP-27 and 0.29 6 0.06 1024
min21/(pmol/l) for PACAP-38 vs. 0.46 6 0.02 1024 min21/
(pmol/l) for controls (P , 0.01)]. Furthermore, PACAP-27 or
PACAP-38 did not affect glucose elimination determined as
glucose half-time or the glucose elimination rate after glucose
injection or the area under the curve for glucose. Moreover,
glucose effectiveness and the global disposition index
(AUCinsulin times SI) were not affected by PACAP-27 or
PACAP-38. Finally, when given together with glucose,
PACAP-27 did not alter plasma glucagon or norepinephrine
levels but significantly increased plasma epinephrine levels.
We conclude that PACAP, besides its marked stimulation of
insulin secretion, also inhibits insulin sensitivity in mice, the
latter possibly explained by increased epinephrine. This
complex action explains why the peptide does not enhance
glucose disposal.
pituitary adenylate cyclase-activating polypeptide; glucose
effectiveness; minimal model
THE NEUROPEPTIDE pituitary adenylate cyclase-activat-
ing polypeptide (PACAP) was originally isolated from
the ovine hypothalamus (26) and has later been shown
to be expressed in several tissues throughout the body
(6). The peptide exists in two forms: PACAP-38 and
PACAP-27, of which the latter is equivalent to
PACAP-38-(1—27) (27). In the pancreas, PACAP has
been localized to intrapancreatic nerve ganglia and to
single nerves in the exocrine parenchyma, around
blood vessels, and in conjunction with islets (2, 15), and
one study has also indicated that PACAP occurs in islet
endocrine cells (34). Furthermore, PACAP receptors
have been demonstrated in the pancreas and in insulin-
producing cells (2, 6, 17, 33). Moreover, PACAP has
been demonstrated to stimulate insulin secretion in
vivo in humans and dogs (13, 21), in vitro in the
perfused rat pancreas (10, 35), and in insulin-produc-
ing cells (2, 3, 17, 22, 34), mainly through activating
adenylate cyclase (3, 22). Hence, PACAP is a pancreatic
neuropeptide with a stimulatory action on insulin
secretion. However, the potential involvement of PACAP
in glucose homeostasis is not established, since the
peptide has also been demonstrated to stimulate the
secretion of glucagon (10, 13, 15, 29, 35) and catechol-
amines (6, 21) as well as to induce glycogenolysis (29,
36), the net effect being hyperglycemia. Also, both the
stimulation of glucagon and catecholamines and the
hyperglycemia induced through stimulation of glycogen-
olysis might indirectly influence insulin secretion and
the glucose disposal rate. Therefore, the integrated
influence of PACAP on the glucose homeostasis might
be complex.
The aim of the present study was to examine in more
detail the in vivo influence of PACAP on insulin secre-
tion, insulin sensitivity, and glucose disposal after an
intravenous glucose challenge in anesthetized mice. To
that end, we exploited the minimal model of glucose
disappearance for glucose and insulin data analysis
after an intravenous glucose tolerance test (8, 14) with
seven samples over 50 min in mice. This method
allowed estimation of acute insulin secretion, total
insulin secretion, insulin sensitivity (the ability of
insulin to enhance glucose disappearance and to inhibit
glucose production), glucose effectiveness (glucose dis-
appearance per se at basal insulin without any change
in insulin), and the glucose elimination rate. We also
examined the influence of PACAP on glucagon secre-
tion and on plasma levels of norepinephrine and epi-
nephrine, and, finally, we compared the influences of
PACAP-27 with those of PACAP-38.
METHODS
Animals. Nonfasted NMRI mice (Bomholdtgaard Breeding
and Research Center, Ry, Denmark), weighing 20–25 g, were
used throughout the study. The animals were fed a standard
pellet diet and tap water ad libitum.
Intravenous glucose tolerance test. The mice were anesthe-
tized with an intraperitoneal injection of midazolam (Dormi-
cum, 0.4 mg/mouse; Hoffmann-La Roche, Basel, Switzerland)
and a combination of fluanison (0.9 mg/mouse) and fentanyl
(0.02 mg/mouse; Hypnorm; Janssen, Beerse, Belgium). There-
after, a blood sample was taken from the retrobulbar, intraor-
bital, capillary plexus in heparinized tubes, whereafter
D-glucose (1 g/kg; British Drug Houses, Poole, UK) was
injected rapidly intravenously either alone or together with










synthetic ovine PACAP-27 or synthetic ovine PACAP-38 at
various dose levels (both peptides from Peninsula Europe
Laboratories, Merseyside, UK). In two other experimental
series, human insulin (Actrapid; Novo Nordisk, Bagsvaerd,
Denmark) was injected intravenously (0.25 U/kg) together
with glucose, or PACAP-27 (1.3 nmol/kg) was injected intrave-
nously under baseline conditions (i.e., without any concomi-
tant glucose injection; controls were given saline). The vol-
ume load was 10 µl/g body wt. New blood samples were taken
after 1, 5, 10, 20, 30, and 50 min. In the experiments on
circulating glucagon and catecholamines, synthetic ovine
PACAP-27 was injected intravenously at a dose level of 1.3
nmol/kg alone or together with glucose (1 g/kg), and blood was
sampled immediately before and at 1, 5, 20, and 50 min after
the injection. The samples for glucose and insulin were taken
in heparinized tubes, the samples for glucagon were taken in
chilled tubes containing aprotinin, and the samples for cate-
cholamines were taken in chilled tubes containing heparin
and EDTA. After immediate centrifugation at 4°C, plasma
was separated and stored at 220°C or 280°C until analysis.
Analysis. Plasma insulin was determined radioimmuno-
chemically with the use of a guinea pig anti-rat insulin
antibody, 125I-labeled porcine insulin as tracer, and rat insulin
as standard (Linco Research, St. Charles, MO). Free and
bound radioactivity was separated by use of an anti-
immunoglobulin G (IgG) (goat anti-guinea pig) antibody
(Linco). The sensitivity of the assay is 12 pmol/l, and the
coefficiency of variation is ,3% at both low and high levels.
Plasma glucose was determined with the glucose oxidase
method. Plasma glucagon was determined radioimmuno-
chemically with the use of guinea pig antiglucagon antibodies
specific for pancreatic glucagon, 125I-labeled glucagon as
tracer, and glucagon standard (Linco). Free and bound radio-
activity was separated by use of an anti-IgG (goat anti-guinea
pig) antibody (Linco). The sensitivity of the assay is 7.5 pg/ml,
and the coefficiency of variation is ,9% at both low and high
levels. Plasma catecholamines were determined by liquid
chromatography in combination with electrochemical detec-
tion, as previously described (28).
Data analysis. Insulin and glucose data from the seven-
sample intravenous glucose tolerance test were analyzed
with the minimal model technique (9). The model assumes a
first-order nonlinear insulin controlled kinetic and accounts
for the effect of insulin and glucose itself on glucose disappear-
ance after exogenous glucose injection. It provides the param-
eter SI (insulin sensitivity index), which is defined as the
ability of insulin to enhance glucose disappearance and
inhibit glucose production (8), and the parameter SG, which is
the glucose effectiveness, representing glucose disappearance
per se from plasma without any change in dynamic insulin
(1). The parameter SG is composed of a glucose disposal action
of basal insulin, the parameter BIE (basal insulin effect), and
the parameter GEZI (glucose effectiveness at zero insulin),
which is the glucose disposal without any influence of insulin
(19). Acute insulin secretion (AIR) was calculated as the mean
of suprabasal 1- and 5-min insulin levels, and the areas under
the curve for insulin (AUCinsulin) and glucose (AUCglucose) were
assessed using the trapezoidal rule of suprabasal values.
Finally, we also calculated a unitless index called GDI (global
disposition index) by multiplying SI times AUCinsulin. The
glucose elimination rate after the glucose injection (KG) was
calculated using the half-time (t1⁄2) for minutes 1–20 after
glucose injection after logarithmic transformation of the
individual plasma glucose values. In the experiment on basal
levels, AUCinsulin, the AUC for glucagon (AUCglucagon), and
AUCglucose were calculated using the trapezoid rule of data
with basal levels subtracted.
Statistics. Means 6 SE are shown. Statistical analyses
were performed with the SPSS for Windows system. Analysis
of the normal distribution was performed with the Kol-
mogorov-Smirnov goodness-of-fit test. Statistical compari-
sons between groups were performed with the nonparametric
Mann-Whitney U-test, since several of the parameters did
not display normal distribution. Pearson’s product moment
correlation was used to estimate linear relationships between
normally distributed variables. The coefficient of variation of
estimated parameters was given by the percent ratio between
the SD and the absolute values. The SD was obtained by the
square root of the main diagonal of the covariance matrix
calculated during the least square estimation procedure (30).
RESULTS
Circulating insulin and glucose after intravenous
glucose or saline. In the control mice not given PACAP,
the rapid intravenous injection of glucose (1 g/kg)
raised plasma insulin levels from 438 6 32 to 2,088 6
191 pmol/l after 1 min (n 5 54; P , 0.001; Fig. 1).
Thereafter, plasma insulin levels rapidly returned to-
ward baseline values. The plasma insulin level decline
exhibited two phases, with a first phase during the first
Fig. 1. Plasma insulin and glucose immediately before and at 1, 5,
10, 20, 30, and 50 min after iv injection of glucose (1 g/kg, n 5 54) or
saline (n 5 14) in anesthetized mice. Means 6 SE are shown.










10 min (t1⁄2 4.9 6 0.5 min) and a second phase after the
first 10 min (t1⁄2 24.7 6 2.7 min). Also, plasma glucose
levels peaked at 1 min after the intravenous glucose
injection (28.5 6 0.7 vs. 9.6 6 0.3 mmol/l at baseline,
P , 0.001), whereafter plasma glucose levels declined
with an elimination half-life of suprabasal glucose of
9.7 6 0.8 min for the first 10 min after glucose injection
(Fig. 1). The half-life of circulating glucose correlated
significantly and inversely to AIR (r 5 20.30, P 5
0.024) but not to the AUCinsulin [r 5 20.06, not signifi-
cant (NS)]. However, AUCinsulin correlated significantly
to the plasma glucose level at 50 min after glucose
injection (r 5 20.41, P , 0.001). The glucose elimina-
tion rate determined as the KG value was 4.2 6
0.1%/min. The KG value correlated to AIR (r 5 0.48, P ,
0.001) but not to AUCinsulin (r 5 0.001, NS). Figure 1 also
shows that the single injection of saline did not signifi-
cantly increase circulating insulin or glucose during
the 50-min study period.
Effects of PACAP-27 and PACAP-38 on glucose-
stimulated insulin secretion. When PACAP-27 or
PACAP-38 was administered intravenously at various
dose levels together with glucose at 1 g/kg, it was found
that the two peptides equipotently and equiefficiently
potentiated glucose-stimulated insulin secretion (Fig.
2). The half-maximal response for the two peptides was
obtained at a dose level of ,33 pmol/kg. At the maxi-
mally effective dose for both peptides, 130 pmol/kg,
insulin secretion, as determined by the AUCinsulin, was
approximately twofold potentiated (P , 0.001).
Effects of PACAP-27 and PACAP-38 on glucose disap-
pearance. Both PACAP-27 and PACAP-38 at 1.3 nmol/kg
potentiated the glucose-induced increase in plasma
insulin levels (Fig. 3). Thus plasma insulin levels in the
1-min sample were increased more than twofold by
either of the peptides (P , 0.001). However, in spite of
the marked increase in plasma insulin after administra-
tion of PACAP together with glucose, glucose elimina-
tion rate was not altered, as is evident from Fig. 3,
bottom, showing an almost identical reduction in circu-
lating glucose after the 1-min peak. This is also evident
from the calculation of the KG value, which was 4.2 6
0.1%/min in controls vs. 3.9 6 0.2%/min after glucose
plus PACAP-27 and 4.3 6 0.2%/min after glucose plus
PACAP-38 (NS).
The data for circulating insulin and glucose were
used for the estimation of the parameters of the mini-
mal model. Table 1 shows the mean and SE for all
control mice injected with glucose alone (n 5 54). In the
Kolmogorov-Smirnov goodness-of-fit test, baseline insu-
lin, SI, BIE, and GDI did not show a normal distribution
(P , 0.05), whereas the other parameters did (P .
0.05). The accuracy of parameter estimation was evalu-
ated with the coefficients of variation of the estimates,
the values of which for the single groups of experiments
are reported in Table 2. Table 3 shows the parameters
estimated from the minimal model injected with
PACAP-27 and PACAP-38. It is seen that AUCinsulin and
Fig. 2. Area under the curve for suprabasal plasma insulin levels
during 50 min [on y-axis, shown as area under the curve for insulin
(AUCinsulin)] after iv administration of pituitary adenylate cyclase-
activating polypeptide (PACAP)-27 or PACAP-38 at various dose
levels together with glucose (1 g/kg) expressed as percent mean of the
respective control animals run in the same experimental series.
Groups without PACAP consisted of 24 animals each, group with
PACAP-27 at 1.3 nmol/kg consisted of 16 animals, and group with
PACAP-38 at 1.3 nmol/kg consisted of 24 animals, whereas the other
groups consisted of 6–12 animals each. Means 6 SE are shown.
Fig. 3. Plasma insulin and glucose immediately before and at 1, 5,
10, 20, 30, and 50 min after iv injection of glucose (1 g/kg) alone or
together with either PACAP-27 or PACAP-38 at 1.3 nmol/kg in
anesthetized mice. Means 6 SE are shown. There were 16 mice in
each of the two experimental groups with glucose 6 PACAP-27 and
24 mice in each of the two experimental groups with glucose 6
PACAP-38.










AIR were both significantly increased by PACAP-27
and PACAP-38, whereas AUCglucose was not altered by
either of the two peptides. Furthermore, SI was reduced
both by PACAP-27 and PACAP-38, whereas SG was not
altered significantly. However, the two components of
SG were both significantly altered, since both PACAP-27
and PACAP-38 increased GEZI but inhibited BIE. The
unitless GDI, finally, was not significantly affected by
PACAP-27 or PACAP-38, since the reduction in SI and
the increase in AUCinsulin compensated each other.
Effects of intravenous insulin on circulating insulin
and glucose. To examine whether the increase in plasma
insulin after injection of PACAP-27 or PACAP-38,
albeit marked, was insufficient to increase glucose
elimination in mice, a separate experiment was under-
taken in which insulin was injected intravenously (0.25
U/kg) together with glucose (1 g/kg). Figure 4 shows
that this insulin injection increased plasma insulin to
4,783 6 416 pmol/l, i.e., by the same degree as injection
of PACAP-27 or PACAP-38 at 1.3 nmol/kg (cf. Fig. 3).
However, in contrast to the failure of PACAP-27 or
PACAP-38 to augment glucose elimination, insulin
clearly increased glucose elimination. Thus the 5-min
plasma glucose values were 20.4 6 0.4 mmol/l in the
absence of insulin injection vs. 17.3 6 0.6 mmol/l in the
presence of insulin injection (P 5 0.002), and the
corresponding 20-min values were 12.3 6 0.4 vs. 7.1 6
0.6 mmol/l (P , 0.001). Furthermore, insulin increased
the KG value from 3.9 6 0.2%/min in controls to 6.1 6
0.2%/min (P 5 0.030). The calculated half-life of circu-
lating insulin for the first 5 min after the insulin
injection was 2.5 6 0.1 min, which is lower than that
previously reported in humans and pigs (25, 32).
Effects of PACAP-27 on glucagon levels. When
PACAP-27 was injected intravenously under baseline
conditions (1.3 nmol/kg), plasma glucagon levels were
increased concomitantly with an increase in insulin
and glucose levels (Fig. 5). Thus the AUCglucagon during
the 50 min was 981 6 86 pg/ml in 50 min after injection
of PACAP-27 vs. 77 6 8 pg/ml in 50 min after adminis-
tration of saline (P , 0.001). Similarly, the AUCinsulin
was 4.9 6 0.5 nmol/l in 50 min after PACAP-27 vs.
21.0 6 0.2 nmol/l in 50 min in controls (P , 0.001), and
the AUCglucose was 213 6 2 mmol/l in 50 min after
PACAP-27 vs. 279 6 7 mmol/l in 50 min in controls
(P , 0.001). In contrast, when PACAP was injected
together with glucose, no significant change in gluca-
gon levels was evident when compared with animals
injected with glucose alone (Fig. 6).
Effects of PACAP-27 on catecholamine levels. When
PACAP-27 was injected intravenously (1.3 nmol/kg)
together with glucose, plasma epinephrine levels were
significantly elevated at both 1 min (P 5 0.004) and 5
min (P 5 0.013) after injection when compared with
animals injected with glucose alone (Fig. 7, top). The
change in plasma epinephrine at 1 min after injection
was 0.87 6 0.34 ng/ml in animals injected with
PACAP-27 plus glucose vs. 20.39 6 0.22 ng/ml in
animals injected with glucose alone (P 5 0.039). In
contrast, plasma norepinephrine was not significantly
altered in any of the two groups of animals after the
injection (Fig. 7, bottom).
DISCUSSION
We have examined the net influences of PACAP-27
and PACAP-38 on insulin secretion, insulin sensitivity,
and glucose disposal in normal mice to study the
integrated action of the pancreatic insulinotropic neuro-
peptide PACAP on the glucose homeostasis. The net
action of PACAP is of interest not only physiologically
but also since it may be suggested that agents which
increase the formation of cAMP may be of potential
interest in the treatment of diabetes. For example,
glucagon-like peptide 1, which raises cAMP, has been
considered as a new regimen in the treatment of type 2
diabetes (16). Our present results confirm previous
studies in dogs and humans that PACAP stimulates
insulin secretion, which also confirms several previous
studies in vitro verifying that PACAP exerts its action
directly on the insulin-producing cells (2, 3, 10, 13, 17,
21, 22, 34, 35). We also show that the insulinotropic
Table 1. Baseline, nonfasted levels of glucose
and insulin and parameters calculated from
the seven-sample minimal model in control
mice intravenously injected with glucose
Parameter Means6SE
P Value for Test
of Normality
Baseline plasma glucose, mmol/l 9.360.3 0.89
Baseline plasma insulin, pmol/l 438646 0.02*
AIR, nmol/l 1.460.1 0.09
AUCinsulin, nmol/l in 50 min 39.862.5 0.15
AUCglucose, mmol/l in 50 min 719620 0.80
SI, 1024 min21/(pmol/l) 0.4660.02 0.05*
SG, min21 0.04260.004 0.42
GEZI, min21 0.02060.005 0.78
BIE, min21 0.02260.003 0.02*
GDI 1.960.2 0.01*
Means 6 SE and the P value for test of normality of the distribution
of the parameters according to the Kolmogorov-Smirnov goodness of
fit; n 5 54 mice. Glucose was administered in a dose of 1 g/kg. AIR,
acute insulin response to glucose (1–5 min suprabasal circulating
insulin); AUC, area under the curve for the entire 50-min period for
insulin (AUCinsulin) and glucose (AUCglucose); SI, insulin sensitivity
index; SG, measure of glucose effectiveness. SG consists of the
parameters GEZI (glucose effectiveness at 0 insulin) and BIE (basal
insulin effect). GDI is the unitless global disposition index, which is
calculated by multiplying SI times AUCinsulin. *P , 0.05.
Table 2. Coefficients of variation of the estimated
parameters, SI and SG, in the various sets
of experiments
Experimental Series Group SI SG








Values are means 6 SE in %; n, no. of mice. PACAP, pituitary
adenylate cyclase-activating polypeptide. Nos. in parentheses are
minimum and maximum values.










action of PACAP-27 and PACAP-38 is equipotent and
equiefficient, which confirms previous results in other
models (2, 21, 34, 35).
In our previous study on the influence of PACAP-38
on insulin secretion in unanesthetized mice, PACAP-38
did not increase plasma insulin, either under baseline
conditions or in conjunction with glucose, and in combi-
nation with the cholinergic agonist carbachol, PACAP-38
actually inhibited insulin secretion (15). In contrast, in
the present study, PACAP potently increased plasma
insulin levels both under basal conditions and in the
presence of glucose. Although a potentially diminished
insulin elimination by PACAP has not been studied,
such an effect is unlikely to explain the rapid and
marked increase in plasma insulin after PACAP admin-
istration, since the magnitude of the increase far
exceeds what is possible, even with a complete inhibi-
tion of insulin elimination. Therefore, a stimulated
insulin secretion most likely explains the marked in-
crease in plasma insulin executed by PACAP. The
mechanism of this potent insulinotropic action of PACAP
cannot be established from the results of this in vivo
study. It could theoretically be due to indirect actions of
PACAP through the liberation of other insulinotropic
agents by the neuropeptide. It could also be due to a
compensatory response to a primary reduction in insu-
lin sensitivity by PACAP. However, the most likely
mechanism, considering the potent insulinotropic ac-
tion of PACAP on isolated islets and insulin-producing
tumor cells (2, 3, 10, 17, 22, 34, 35), is a direct action on
the islets. Furthermore, PACAP-38 also increased circu-
lating glucagon, which confirms our previous study in
unanesthetized mice (15). This is most likely executed
through stimulation of glucagon secretion from the
pancreatic islets. In our previous study in unanesthe-
tized mice, glucose could not inhibit the glucagon
response to PACAP-38 (15), which is different from the
abolishment by glucose of PACAP-induced glucagon
secretion in the present study in anesthetized mice. It
is likely that stress-related phenomena in unanesthe-
tized mice also account for this difference. Hence, the
present model in anesthetized animals seems to more
reliably show the direct action of PACAP on islet
function, when stress-related actions are circum-
vented. It should also be emphasized that our present
result of potentiated glucose-stimulated insulin secre-
tion and increased baseline glucagon secretion in re-
sponse to PACAP in mice is identical to the results
of our recent report on the action of PACAP-27 in
humans (13).
The main new finding in this study is that, in spite of
a marked insulinotropic action of PACAP, the glucose
disposal was not augmented. This was evident by
calculating the area under the curve for plasma glucose
levels during the entire 50-min test as well as the
glucose elimination rate for the 20 min after glucose
administration and the t1⁄2 of glucose after glucose
administration. We interpret this finding to be due to
the marked (by ,50%) inhibition of insulin sensitivity
induced by PACAP, as evident from the minimal model
data of the insulin sensitivity index. The potentiated
insulin secretion and the inhibited insulin sensitivity
thus together compensated each other, the consequence
of which was the unaltered glucose disposal. Conse-
quently, also the global disposition index, which quanti-
fies the capacity to compensate a change in insulin
secretion or insulin sensitivity with a comparable in-
Table 3. Baseline, nonfasted levels of glucose and insulin and parameters calculated from the seven-sample
minimal model in mice intravenously injected with glucose (1 g/kg) either alone or together with PACAP-27
(1.3 nmol/kg) or PACAP-38 (1.3 nmol/kg)
Parameter
Experimental Series with PACAP-27 Experimental Series with PACAP-38
Controls (n516) P PACAP-27 (n516) Controls (n524) P PACAP–38 (n524)
Baseline plasma glucose, mmol/l 9.160.7 NS 8.360.7 9.660.3 NS 9.860.4
Baseline plasma insulin, pmol/l 432638 NS 469641 441692 NS 4866134
AIR, pmol/l 1.660.2 0.001 3.860.4 1.360.2 ,0.001 3.360.3
AUCinsulin, nmol/l in 50 min 39.463.1 0.029 70.3610.1 40.064.6 ,0.001 64.665.9
AUCglucose, mmol/l in 50 min 681634 NS 682643 744638 NS 672633
SI, 1024 min21/(pmol/l) 0.4860.08 0.005 0.2360.04 0.6860.09 ,0.001 0.2960.06
SG, min21 0.04060.006 NS 0.04160.005 0.04360.006 NS 0.05760.008
GEZI, min21 0.02060.008 0.046 0.02960.006 0.01960.008 0.027 0.04660.008
BIE, min21 0.02060.003 0.046 0.01260.002 0.02460.006 0.020 0.01160.003
GDI 1.760.2 NS 1.260.1 2.160.2 NS 1.660.3
Values are means 6 SE; n, no. of mice. P, probability level of random difference between mice injected with PACAP-27 or PACAP-38 and
their respective controls as determined by Mann-Whitney U-test. NS, not significant.
Fig. 4. Plasma insulin and glucose immediately before and at 1, 5,
20, and 50 min after iv injection of glucose (1 g/kg) alone or together
with human insulin (0.25 U/kg) in anesthetized mice. Means 6 SE
are shown. There were 6 mice in each group.










verse change in the other parameter, was not signifi-
cantly altered by PACAP.
The reason for the marked reduction in insulin
sensitivity by PACAP is at present not clear. Several
hypothetical explanations might be offered, however.
One hypothesis is that the rapid and marked increase
in plasma insulin had compensatorily reduced insulin
sensitivity and thereby prevented its own action to
enhance glucose elimination. This in turn would sug-
gest that the reduction in glucose levels during an
intravenous glucose tolerance test is largely indepen-
dent of insulin. Previous reports in rats have indeed
indicated this to be the case. Thus at 3 h after prolonged
hyperglycemia in rats, the glucose elimination after an
intravenous glucose challenge has been found to be
unaltered in spite of an exaggerated insulin response
(23), and, furthermore, cholinergic antagonism by atro-
pine has been found to markedly inhibit glucose-
stimulated insulin secretion in rats preinfused for 48 h
with glucose without altering the glucose disposal rate
(7). To examine this intriguing possibility, we adminis-
tered insulin intravenously at the dose of 0.25 U/kg
together with glucose. This yielded a circulating insulin
level of approximately the same degree as that seen
after PACAP plus glucose. However, we found that
insulin under this condition clearly augmented glucose
elimination. This therefore shows that a rapid reduc-
tion in insulin sensitivity simply due to the rapidly
increasing circulating levels of insulin is not the expla-
nation for the failure of PACAP to augment glucose
disposal. Another hypothesis, which more likely would
explain the reduced insulin sensitivity by PACAP, is
that other insulin-antagonistic actions counteracting
the insulin effect have evolved after PACAP administra-
tion. Such insulin-antagonistic actions could be either
PACAP itself, if PACAP directly reduces or counteracts
the action of insulin. It could also, however, be due to
other factors, the secretion of which would be stimu-
Fig. 5. Plasma insulin, glucagon, and glucose immediately before
and at 1, 5, 20, and 50 min after iv injection of saline or PACAP-27
(1.3 nmol/kg) in anesthetized mice. Means 6 SE are shown. There
were 8 mice in each group.
Fig. 6. Plasma insulin, glucagon, and glucose immediately before
and at 1, 5, 20, and 50 min after iv injection of glucose (1 g/kg) without
or with addition of PACAP-27 (1.3 nmol/kg) in anesthetized mice.
Means 6 SE are shown. There were 6 mice in each group.










lated by PACAP and which in vivo could prevent the
action of insulin. An antagonistic action of PACAP itself
on glucose elimination would be supported by data that
mice injected with PACAP had elevated glucose levels
when compared with mice injected with saline (cf. Fig.
5) and by previous reports that PACAP stimulates the
hepatic glucose delivery (29, 36). However, although
this is a possibility under baseline conditions, it is
unlikely to be a mechanism after a glucose challenge,
since glucose inhibits liver glucose delivery (11). The
other possible factors that could counteract the glucose
reduction after PACAP administration are glucagon
and catecholamines. Thus previous reports have demon-
strated that PACAP stimulates glucagon secretion from
the pancreas (10, 13, 15, 21, 29, 35) and epinephrine
secretion from the adrenals (6, 21). To test these
possibilities, we also determined plasma glucagon and
catecholamines after administration of PACAP-27 to
mice. We found that, although PACAP, as expected
from results of previous studies (10, 13, 15, 21, 29, 35),
increased baseline glucagon levels, the peptide did not
increase plasma glucagon in the presence of elevated
glucose levels, since plasma glucagon levels after the
combined injection of PACAP-27 and glucose were not
significantly different from those after injection of
glucose alone. This is interpreted to indicate that
glucose inhibited PACAP-induced glucagon secretion.
Therefore, the mechanism of the impaired insulin
sensitivity by PACAP under in vivo conditions in mice
is probably not explained by glucagon. In contrast,
plasma epinephrine levels, but not norepinephrine
levels, were elevated after the combined injection of
PACAP-27 and glucose, which might support a role for
epinephrine. Although not directly examined in this
study, such an action of epinephrine could be executed
through activation of the b-adrenoceptors and subse-
quent formation of cAMP, which is a well-known mech-
anism whereby catecholamines induce insulin resis-
tance (24). However, the mechanism of this action
remains to be fully established.
To analyze the data, we have exploited the minimal
model approach to experiments in mice. The frequently
sampled intravenous glucose tolerance test with mini-
mal model analysis was originally developed to quanti-
tate glucose disposal in dogs and humans after a single
intravenous glucose injection (8, 14). The method pro-
vides parameters characterizing insulin and glucose
action on glucose homeostasis (8). This model has
provided a useful and powerful tool for the understand-
ing of glucose disposal under a variety of conditions,
such as impaired glucose tolerance and type 2 diabetes,
and has also been used in pharmacological studies to
examine influences of exogenously administered sub-
stances, such as somatostatin and glucagon-like pep-
tide 1 (5, 8, 9, 12, 14, 19). To the best of our knowledge,
the minimal model has been used in small animals
(rats) only a few times (14). No particular constraint
should exist that restrains the use of this technique
also in mice, being the only arguments about the length
of the experiment and the limited number of samples
(31). The model does not, however, seem to have
problems related to the length of the study period,
since, by the end of the experiments, both insulin and
glucose have returned to preinjection levels, and thus
the entire dynamics of the test are taken into account.
In fact, the low dispersion of the estimates along with
the coefficients of variation demonstrated a precise and
accurate assessment of insulin secretion, insulin sensi-
tivity, and glucose disposal in mice. This seven-sample
technique therefore offers promises to be of importance
in future physiological and pharmacological studies in
mice, as well as in phenotypic characterization of
animal models of interest for glucose homeostasis and
diabetes, although this technique needs to be validated
against other methods for determination of insulin
secretion and insulin sensitivity in mice.
We have previously shown in unanesthetized mice
that an intravenous injection of glucose elicits a marked
and rapid increase in circulating insulin with a peak
level within the first 2 min and a return to baseline
levels within 6 min (4). The elevation of circulating
insulin was more sustained in the anesthetized ani-
mals, which is interpreted as a lower degree of stress
exhibited in these animals, reducing increase in cate-
cholamines with their inhibiting action on insulin
Fig. 7. Plasma epinephrine and norepinephrine immediately before
and at 1, 5, 20, and 50 min after iv injection of glucose (1 g/kg) with
addition of PACAP-27 (1.3 nmol/kg) in anesthetized mice. Means 6
SE are shown. There were 5 mice in each group.










secretion. The seven-sample technique in anesthetized
mice therefore does not seem to be accompanied by any
significant degree of stress, which also is supported by
our finding that there was no increase in basal glucose
in the saline-injected controls.
Glucose elimination is not governed only by insulin-
dependent actions. Thus insulin-independent mecha-
nisms also contribute substantially to the glucose dis-
posal after glucose administration, mainly by insulin-
independent glucose uptake in the brain and in skeletal
muscle and by suppression of liver glucose output
during hyperglycemia (1, 11). The glucose effectiveness
calculated by the minimal model quantifies both of
these processes (11), and it has previously been found
that glucose effectiveness accounts for .20% of the
variance in glucose elimination in healthy subjects (20).
This is the first time the minimal model is applied to
mice; therefore, there is no previous history that allows
comparisons to deeply evaluate the role of glucose
effectiveness. Although it is generally agreed that the
minimal model yields reliable measurements of insulin
sensitivity, it is still the subject of controversy how to
interpret glucose effectiveness in terms of true physi-
ological implications and limitations (11). Nonetheless,
there is a general consensus on its important role in the
comprehension of the mechanisms involved in glucose
disappearance. In the present study, we found that the
glucose effectiveness was not significantly affected by
PACAP. Therefore, the global glucose effectiveness is
not compensatorily increased when insulin sensitivity
is reduced by PACAP, which underlines earlier observa-
tions that insulin sensitivity and glucose effectiveness
can change independently of each other (18). The global
glucose effectiveness is composed of glucose effective-
ness at basal insulin and at zero insulin. Interestingly,
PACAP had significant effects on both of these param-
eters. Thus the peptide inhibited glucose effectiveness
at basal insulin, which is a reflection of its inhibitory
influence on insulin sensitivity. In contrast, PACAP
increased glucose effectiveness at zero insulin. This
latter effect is similar to glucagon-like peptide 1 in a
previous study in humans (12). However, in contrast to
PACAP, glucagon-like peptide 1 had no influence on
glucose effectiveness at basal insulin and therefore
increased global glucose effectiveness (12). The mecha-
nism of an increase in glucose effectiveness at zero
insulin by PACAP might reside in stimulation of glu-
cose uptake in tissues like the skeletal muscle or
inhibition of liver glucose production. The molecular
mechanism of action by PACAP or the site of the action
cannot be determined by the minimal model, however,
and remains therefore to be established directly. In
addition, it is worth pointing out that, despite being
reported in many studies, the basal insulin effect and
glucose effectiveness at zero insulin are still the subject
of debate concerning their true physiological meaning.
For this reason, our conclusions in this respect must be
interpreted as study hypotheses, since it is not possible
to date to draw unquestionable conclusions from the
analysis of the components of glucose effectiveness.
Based on this integrative study on the development
of a seven-sample technique in mice and the influence
of PACAP on insulin secretion, insulin sensitivity, and
glucose disposal, we conclude that 1) PACAP stimu-
lates insulin secretion in a concentration-dependent
manner, 2) the insulinotropic actions of PACAP-27 and
PACAP-38 are equipotent, 3) PACAP inhibits insulin
sensitivity without altering the glucose effectiveness,
4) PACAP stimulates glucagon secretion under basal
conditions but not after administration of glucose, 5)
PACAP-27 increases circulating levels of epinephrine
but not of norepinephrine, 6) the net effect of PACAP
during an intravenous glucose tolerance test is an
unaltered glucose disposal in spite of a marked insulino-
tropic action, and 7) the minimal model of the seven-
sample technique is a reliable model in anesthetized
mice. The study therefore is consistent with and sup-
ports the view that PACAP is involved in the regulation
of insulin secretion but that additional complex actions
are exerted on the net glucose homeostasis. In contrast,
PACAP does not seem to be a good target as a new
reagent in the treatment of diabetes. However, B cell-
specific PACAP receptor agonists, devoid of peripheral
influences counteracting the action of insulin, might
offer a good rational for such development, because
PACAP seems to be an extraordinary potent insulinotro-
pic peptide.
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